Research advances in immune checkpoint treatment for advanced hepatocellular carcinoma
10.3760/cma.j.issn.1673-9752.2020.02.003
- VernacularTitle:晚期肝细胞癌免疫检查点治疗研究进展
- Author:
Xiangcheng LI
1
;
Xiaofeng CHEN
;
Xia ZHENG
Author Information
1. 南京医科大学第一附属医院肝胆中心 210029
- From:
Chinese Journal of Digestive Surgery
2020;19(2):123-129
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy, especially immune checkpoint inhibitors (ICIs), has reformed the situation of cancer management. Encouraging results have been revealed in early stage studies about ICIs in patients with hepatocellular carcinoma.Results of a recent phase Ⅲ study of ICIs combined with anti-angiogenesis therapy in the treatment of hepatocellular carcinoma have achieved a positive result, showing superior advantages in efficacy and safety compared with standard manage-ment. At present, lots of studies in hepatocellular carcinoma patients treated with ICIs combining with traditional therapy like chemotherapy, radiotherapy, antiangiogenetic therapy, locore-gional therapy and another ICIs are held globally. These results will update the strategies of hepatocellular carcinoma.
